Fennec Pharmaceuticals (FENC) Non-Current Debt (2021 - 2022)

Name: Fennec Pharmaceuticals (FENC) Non-Current Debt (2021 - 2022) | Business Quant
Creator: Business Quant

Fennec Pharmaceuticals posted quarterly Non-Current Debt of $25.0 million for Q3 2022, up 525.0% on a QoQ basis from $4.0 million in Q2 2022.

Fennec Pharmaceuticals (FENC) has 2 years of Non-Current Debt data on file, last reported at $25.0 million in Q3 2022.

For the quarter ending Q3 2022, Non-Current Debt changed N/A year-over-year to $25.0 million; the trailing twelve-month figure through Sep 2022 stood at $25.0 million (changed N/A YoY), and the FY2021 full-year result was $5.0 million, changed N/A from the prior year.
Non-Current Debt for Q3 2022 stood at $25.0 million, up from $4.0 million in the prior quarter.
Across five years, Non-Current Debt topped out at $25.0 million in Q3 2022 and bottomed at $4.0 million in Q2 2022.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Non-Current Debt (Qtr)
1	Quantum Biopharma	961,148.99 Bn	961,148.98 Bn	-	-
2	Alterity Therapeutics	744,933.29 Bn	744,933.26 Bn	-	-
3	Legend Biotech	2,540.00 Bn	2,539.71 Bn	242.10 Mn	319.10 Mn
4	Nanobiotix	2,199.85 Bn	2,199.78 Bn	-	105.94 Mn
5	Akari Therapeutics	1,635.88 Bn	1,635.88 Bn	-	-
6	Vertex Pharmaceuticals	111.32 Bn	104.07 Bn	2.59 Bn	-
7	Evaxion A	62.56 Bn	62.54 Bn	-	-
8	Regeneron Pharmaceuticals	62.55 Bn	53.79 Bn	3.31 Bn	1.99 Bn
9	Alnylam Pharmaceuticals	39.57 Bn	36.56 Bn	959.66 Mn	-
10	Fennec Pharmaceuticals	281.48 Mn	244.70 Mn	7.67 Mn	-

Download Data 🔒